[exclusive] Shuanglu's revenue in 2017 was 1.242 billion yuan, reversing the decline in 2018 or relying on these two drugs to keep climbing!

On February 26, Beijing Shuanglu released the performance express In 2017, the company realized an operating revenue of 1.242 billion yuan, a year-on-year increase of 23%, and the net profit attributable to shareholders of the listed company was 537 million yuan, a year-on-year increase of 18.76% (see Figure 1 for specific performance) (Figure 1) on November 18, 2014, Beijing Shuanglu submitted the listing application of its heaviest product, lenalidomide On July 22, 2015, the clinical self-examination broke out and the listing was blocked The performance of Beijing Shuanglu was also greatly affected Since 2014, the operating revenue of Beijing Shuanglu has declined continuously, from 1.243 billion yuan to 1.010 billion yuan in 2016, and the net profit has decreased accordingly Until 2017, the net profit recovered to 537 million yuan (see Figure 2 for 2014-2017 net profit) (Figure 2) from the perspective of product application and approval, Beijing Shuanglu has 238 application records so far, including 196 chemical drugs, 40 biological drugs and 2 traditional Chinese medicines It can be seen from the annual declaration of 2001-2017 (Figure 3) that the number of declaration of Shuanglu in Beijing dropped rapidly after reaching the peak (57) in 2005, and it has been hovering around 10 (Figure 3) by 2017, CDE had accepted 7 product records of Beijing Shuanglu, including 2 chemicals and 5 biological products Two chemical drugs are all for application for reexamination, five biological products are two for application for reexamination, and three are new drugs (including two varieties of long-acting recombinant human follicle stimulating hormone injection and recombinant all human anti TNF - α monoclonal antibody injection, as shown in Figure 4) (Fig 4) Judging from the listed products, at present, there are 120 approved databases of Beijing double egrets in the medicine database, including apricot dripping pills, Arsenic Trioxide for injection, Lenalidomide capsules, Recombinant Human Interleukin-2 for Injection, Loratadine Dispersible Tablets, Coenzyme Complex for Injection, recombinant human basic fibroblast growth factor (gfgf), 7 varieties are exclusive production of Beijing double egret And the latter four varieties have won the bid in 29, 29, 27 and 24 regions, almost all over the country As can be seen from Figure 5, many products of Beijing Shuanglu have won the bid in more than 20 provinces and cities in China, and the product line layout is wide, ranging from tumor, liver disease to metabolic disease and cardio cerebrovascular product line, with obvious advantages in variety and scale In addition, in 2017, the number of bid winning products of Beijing Shuanglu increased from 43 in 2014 to 52 (as shown in Figure 6), which laid a solid foundation for Beijing Shuanglu to win In 2006-2017, the number of winning varieties (Figure 6) two heavyweights are expected to achieve a significant reversal of performance In addition to the market expansion of existing products, the main focus of Beijing Shuanglu this year is on its heavyweight anti-tumor drug lenalidomide Lenalidomide is an immunomodulator anti-tumor drug developed by new base It was first approved by FDA on December 27, 2005, and was used to treat myelodysplastic syndrome Later, it was expanded and approved by FDA to treat multiple myeloma and mantle cell lymphoma In recent years, the sales of naduramine in the world has a rapid growth trend, and the heat is also increasing In January 2017, fierce Pharma ranked the best-selling cancer drugs in the world in 2022, and lenalidomide ranked first with sales of US $13.44 billion In fact, Beijing Shuanglu began to research and develop lenalidomide as early as 10 years ago Until November 30, 2017, it was officially approved for production, which can be described as several setbacks After going public, he and Cavendish, the R & D Party of lenalidomide, have different opinions on the distribution rights Finally, Beijing Shuanglu has transferred the sales royalty right of lainaduandiamine capsule project within the patent period enjoyed by Cavendish with 68 million yuan, and Beijing Shuanglu has really obtained the complete technical rights and interests of lainaduandiamine capsule project, has the right to use such technology, and has the right to produce, sell and promise to sell relevant products At present, only Beijing Shuanglu has obtained the production approval document in China (as shown in Figure 7) The imported specification of 10mg * 21 from Xinji, the average bid price in 2017 is 25190.83 yuan (Figure 7) in addition, the hair and tonic work of ornidazole injection, another heavy-duty variety of Beijing Shuanglu, has been completed before it is approved for production (Figure 8) It is reported that ornidazole is the third generation of nitroimidazole drugs In recent years, ornidazole has been ranked first in the market of other antibacterial drugs in the chemical medicine pattern of public medical institutions in China, and its market share rose to 43.56% in 2015 (Figure 8) if ornidazole injection can also be successfully launched in the near future, on the basis of a slight recovery in the performance of Beijing Shuanglu in 2017, the two heavyweight products will boost the continuous growth of the performance in 2018.